Saturday, July 28, 2018 8:33:34 AM
This action has 2 major effects...
First there are likely few traders left from the sub$1 range now that we had our first pullback/profit taking...they have been replace with what I will call the $1.30 crowd...
Secondly there are fewer shares available in the float now that the new buyers will be holding into the FDA date.
FDA clearance for a device is a less complicated and risky decision vs and FDA approval for a drug... thus we will have far more people holding thru the FDA date...
Next week will be very very interesting to see how my decades of trading experience will play out...good luck!
Recent PAVM News
- PAVmed to Hold a Business Update Conference Call and Webcast on May 14, 2024 • PR Newswire (US) • 05/03/2024 12:35:00 PM
- Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 13, 2024 • PR Newswire (US) • 05/02/2024 12:35:00 PM
- Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Data from National Cancer Institute-Sponsored, Prospective, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing • PR Newswire (US) • 05/02/2024 11:49:00 AM
- PAVmed Subsidiary, Veris Health, Signs Memorandum of Understanding with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute • PR Newswire (US) • 04/30/2024 11:35:00 AM
- Lucid Diagnostics Partners with the Esophageal Cancer Action Network (ECAN) to Highlight Esophageal Cancer Awareness Month • PR Newswire (US) • 04/29/2024 12:47:00 PM
- Lucid Diagnostics to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference • PR Newswire (US) • 04/08/2024 12:30:00 PM
- PAVmed Provides Business Update and Fourth Quarter and Full Year 2023 Financial Results • PR Newswire (US) • 03/26/2024 11:32:00 PM
- Lucid Diagnostics Announces Positive Data from the First Prospective Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population • PR Newswire (US) • 03/21/2024 01:30:00 PM
- PAVmed Launches Incubator to Advance Existing Pipeline Technologies including PortIO, EsoCure and CarpX • PR Newswire (US) • 03/21/2024 12:30:00 PM
- Lucid Diagnostics Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference • PR Newswire (US) • 03/20/2024 12:30:00 PM
- PAVmed to Hold a Business Update Conference Call and Webcast on March 27, 2024 • PR Newswire (US) • 03/13/2024 12:30:00 PM
- Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 26, 2024 • PR Newswire (US) • 03/12/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/08/2024 09:30:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 09:49:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 09:46:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 09:43:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 09:41:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/20/2024 09:49:05 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 02/20/2024 09:45:37 PM
- Lucid Diagnostics Provides Update Regarding World Trade Center Health Program • PR Newswire (US) • 02/16/2024 10:00:00 PM
- Lucid Diagnostics Chairman & CEO, Dr. Lishan Aklog, Highlights EsoCheck® Esophageal Cell Collection Device during Congressional Testimony • PR Newswire (US) • 02/15/2024 12:45:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 08:38:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2024 09:30:41 PM
- Lucid Diagnostics Executes Contract to Provide EsoGuard® Esophageal Precancer Testing as a Covered Benefit for 9/11 Responders and Survivors • PR Newswire (US) • 02/08/2024 12:45:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 02/06/2024 10:17:42 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM